Comparative Pharmacology
Head-to-head clinical analysis: METHIMAZOLE versus THYROSAFE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHIMAZOLE versus THYROSAFE.
METHIMAZOLE vs THYROSAFE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits thyroid peroxidase, thereby blocking the synthesis of thyroid hormones (T3 and T4). Also inhibits peripheral conversion of T4 to T3.
THYROSAFE is a thyroid hormone replacement therapy containing levothyroxine, a synthetic T4 hormone. It exerts its physiological effects by binding to thyroid hormone receptors (TRα and TRβ) in target tissues, modulating gene transcription and cellular metabolism.
Oral, initial dose 15-40 mg daily in 3 divided doses; maintenance dose 5-15 mg daily
Initial: 0.075 mg orally once daily; adjust dose every 2-4 weeks based on TSH. Typical maintenance dose: 0.05-0.15 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateMethimazole + Prednisolone
"The serum concentration of Prednisolone can be decreased when it is combined with Methimazole."
Clinical Note
moderateMethimazole + Artesunate
"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Methimazole resulting in a loss in efficacy."
Clinical Note
moderateMethimazole + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methimazole."
Clinical Note
moderate4-6 hours in euthyroid patients; prolonged to 10-15 hours in hyperthyroid patients. Clinical context: steady-state achieved in 2-3 days, but therapeutic effect on thyroid hormone synthesis requires 3-8 weeks due to depletion of stored hormones.
Terminal elimination half-life is 12-18 hours (mean 15 hours). In hyperthyroidism, clearance may be increased; in renal impairment, half-life prolonged.
Primarily renal (65-70% as unchanged drug and metabolites), with minor biliary/fecal elimination (<10%).
Primarily renal (60-80%) as unchanged drug; 20-40% as glucuronide conjugates; minimal biliary/fecal (<5%).
Category D/X
Category C
Antithyroid Agent
Antithyroid Agent
Methimazole + Clozapine
"The risk or severity of adverse effects can be increased when Methimazole is combined with Clozapine."